Categories
Hematology Myeloma Oncologist

Newest Treatment for Multiple Myeloma | Dr. Rafael Fonseca

Rafael Fonseca, MD

Role:Interim executive director, hematologist-oncologist
Focus:Multiple myeloma, new drug development
Institution:Mayo Clinic

Newest Treatment for Multiple Myeloma (2021)

Rafael Fonseca, MD

Dr. Rafael Fonseca has been a practicing hematologist for almost three decades, now interim executive director at Mayo Clinic.

As a veteran specialist of the myeloma field, he shares his insights on the latest in emerging treatments and clinical trial studies for this series focused on the newest treatment for multiple myeloma.

Explore below for our five episodes, focused primarily on treatment for relapsed/refractory multiple myeloma patients, with an update from his original interview, including the latest with selinexor.

Patient in hospital receiving chemo
First Line Treatment & Side Effects

This introductory episode focuses on the landscape of front line or first line treatment for multiple myeloma, from induction therapy, the various go-to drugs and how they’re used, personalizing treatment, and the most commonly reported side effects.

Relapsed/Refractory Treatment & Side Effects

Dr. Fonseca describes his typical treatment regimen for multiple myeloma patients who’ve become triple-class refractory. He dives deeper into drugs like selinexor, melflufen, and belantamab mafodotin, as well as commonly reported side effects and how to manage them.

Emerging T-Cell Therapies

Dr. Fonseca shares his insights on emerging T-cell therapies for multiple myeloma, describing the role T-cells play in our bodies and then focusing on chimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers (BiTEs).

The Process of Clinical Trials

In this episode, Dr. Fonseca details the process of clinical trials, as well as how patients and families can better understand what goes on during each of the main parts of the study.

Looking Ahead on Myeloma

Learn more about the newer class of drugs known as “CELMoDs,” the development of preventative vaccines for myeloma and who might benefit, and Dr. Fonseca’s last message for myeloma patients and caregivers.

  • Name: Dr. Rafael Fonseca
  • Role:
    • Hematologist-oncologist
    • Interim director, Mayo Clinic Cancer Center 
    • Director, Innovation and Transformational Relationships at Mayo Clinic (Arizona)
  • Experience: ~30 years
  • Areas of Focus:
    • Clinical trials for myeloma and related conditions
    • Genetics of myeloma
    • New drug development
  • Approach with patients: Understanding & cognizant of difficulties diagnosis brings

Previous Conversations with Dr. Fonseca

Myeloma Basics

Dr. Fonseca covers the general landscape of multiple myeloma, the different types, and standard of care.

»MORE: Basics of Multiple Myeloma

Favorite0

Leave a Reply

Your email address will not be published.